|
Powered by Cell Signaling Technology |
Site Information |
---|
HQRCLAHsLVGTPNY SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 457594 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Regulatory protein: | |
Putative in vivo kinases: | |
Treatments: |
Downstream Regulation | |
---|---|
Effects of modification on LATS1: | |
Effects of modification on biological processes: |
References | |
---|---|
Drozdz MM, et al. (2022) A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation. Cell Rep 40, 111412
36170819 Curated Info |
|
Zuo Y, et al. (2022) LATS1 is a central signal transmitter for achieving full type-I interferon activity. Sci Adv 8, eabj3887
35394840 Curated Info |
|
Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451 Curated Info |
|
Calvo F, et al. (2013) Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15, 637-46
23708000 Curated Info |
|
Guo A (2011) CST Curation Set: 12477; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info |
|
Guo A (2011) CST Curation Set: 12478; Year: 2011; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info |